Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Blood (2012)
  • Raya Mawad, University of Washington
  • Ted A. Gooley, Fred Hutchinson Cancer Research Center
  • Joseph G Rajendran, University of Washington
  • Darrell R. Fisher, Pacific Northwest National Laboratory
  • Ajay K. Gopal, University of Washington
  • H. Joachim Deeg, Fred Hutchinson Cancer Research Center
  • Andrew Shields, University of Washington
  • Damian J. Green, Fred Hutchinson Cancer Research Center
  • David G. Maloney, University of Washington
  • Brenda M. Sandmaier, University of Washington
  • Rainer Storb, Fred Hutchinson Cancer Research Center
  • Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center
  • Oliver W. Press, Fred Hutchinson Cancer Research Center
  • John M. Pagel, University of Washington
Link
Disciplines
Publication Date
November 16, 2012
Citation Information
Raya Mawad, Ted A. Gooley, Joseph G Rajendran, Darrell R. Fisher, et al.. "A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)" Blood Vol. 120 Iss. 21 (2012) p. 1924 - 1924
Available at: http://works.bepress.com/john-pagel/145/